Maximum-intensity projection images from [68Ga]Ga-PSMA and [18F]-FDG PET before treatment, and [177Lu]Lu SPECT displayed without and with (red) segmentation with SUV of >3 in 74-y-old mCRPC patient. (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

Maximum-intensity projection images from [68Ga]Ga-PSMA and [18F]-FDG PET before treatment, and [177Lu]Lu SPECT displayed without and with (red) segmentation with SUV of >3 in 74-y-old mCRPC patient.

Caption

Figure 2: Maximum-intensity projection images from [68Ga]Ga-PSMA and [18F]-FDG PET before treatment, and [177Lu]Lu SPECT displayed without and with (red) segmentation with SUV of >3 in 74-y-old mCRPC patient. [177Lu]Lu-PSMA therapy was stopped at third injection despite dramatic decrease in PSA because of lack of favorable impact on symptoms and worsening clinical condition, and patient died 6 months later. High TLA was observed after second and third injections with advent of new bone lesions (orange arrows), both being indicative of poor prognosis.

Credit

Image created by L Imbert and C Boursier, et al., Regional University Hospital Center in Nancy, France.

Usage Restrictions

Please give appropriate credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.